5 mg vial
ARA-290 5 mg vial: how to reconstitute it
What a 5 mg vial of ARA-290 becomes once it is mixed, and what each dose reported in the sources draws to on a syringe. Every figure is arithmetic on the vial size in the heading — none of it is a recommendation, and the doses are the ones our sources describe rather than ones we picked.
Leading with
5 mg + 1 mL bacteriostatic water = 5 mg/mL
Chosen because it puts the reported doses on readable marks of a 1 mL U-100 syringe. Other volumes are perfectly valid — the dilution table further down covers them, and the concentration changes what every dose draws to.
What each reported dose draws to
At 5 mg/mL, on a 1 mL U-100 syringe. Every row names the source it came from, and a trial protocol and a community convention are not the same kind of information.
| Goal | Dose | Units | Doses in this vial | Source |
|---|---|---|---|---|
| Phase 2 protocol for small fibre neuropathyOnce daily for 28 days · Subcutaneous | 4 mg | 80 units | 1 | Clinical trial |
| Commonly described community protocolOnce daily in courses of several weeks · Subcutaneous | 1 mg – 4 mg | 20 units – 80 units | 5 | Community practice |
Check every figure against the vial in front of you before drawing. Vials are filled with an overage and labels are not a guarantee. Change any of these numbers in the calculator.
Week by week
Published schedules only. Most compounds on this site have no week-by-week schedule from any source, and where that is the case this section does not appear rather than being filled in.
Reported community progression
Community practice| Week | Dose | Units | Frequency |
|---|---|---|---|
| 1 | 2 mg | 40 units | Once daily |
| 2–8 | 4 mg | 80 units | Once daily |
A progression described in community sources, not a finding. No dose-ranging study establishes these steps, and the compilation they come from contained arithmetic errors in its own syringe figures — so the doses are reproduced and none of its unit conversions are.
What the whole schedule costs
Vials of this size needed to work through each step, at 1 mL per vial. The dose changes as you go, so this is not one number times a number of weeks — it is each step costed separately and added up.
Reported community progression
| Week | Dose | Doses | 5 mg vials |
|---|---|---|---|
| 1 | 2 mg | 7 | 4 |
| 2–8 | 4 mg | 49 | 49 |
Reaching the end of the defined steps takes 53 vials of 5 mg over 8 weeks.
Steps whose dose exceeds this vial are marked rather than counted — at that point a larger vial is the answer, not more small ones. Nothing here accounts for a dropped vial, a held step or a dose your prescriber changes, all of which happen.
If you add a different amount of water
The same 5 mg of compound, at four common volumes. More water means a larger, easier-to-measure draw of a weaker solution; less water means the opposite. The amount of compound you inject is identical in every row — only the volume carrying it changes.
| Water added | Concentration | 4 mg draws to |
|---|---|---|
| 1 mLshown above | 5 mg/mL | 80 units units · 0.8 mL |
| 2 mL | 2.5 mg/mL | Exceeds a 1 mL barrel |
| 3 mL | 1.667 mg/mL | Exceeds a 1 mL barrel |
| 5 mL | 1 mg/mL | Exceeds a 1 mL barrel |
Storage
Before mixing
Refrigerated at 2–8 °C, protected from light.
After mixing
Refrigerated at 2–8 °C. Do not freeze once mixed.
Other vial sizes
The same compound, different arithmetic.
Arithmetic on the vial size named above and the doses our sources report. Nothing here is a recommendation, a protocol or medical advice, and no clinician has reviewed it. Some rows describe community practice, which is not evidence that a dose is safe or effective. Speak to a licensed healthcare provider before acting on any of it.
Sources for the doses above are listed in full on the ARA-290 profile, each with the trial or label it came from.